<DOC>
	<DOCNO>NCT00099203</DOCNO>
	<brief_summary>This 2 arm study compare efficacy intravenous Bondronat zoledronic acid patient malignant bone disease experience moderate severe pain . Patients randomize receive either Bondronat ( 6mg iv day 1 , 2 3 every 3-4 week ) zoledronic acid ( 4mg iv day 1 every 3-4 week ) . The anticipated time study treatment 6-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Assess Efficacy Intravenous Bondronat ( Ibandronate ) Patients With Malignant Painful Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>patient malignant bone disease ; patient moderate severe pain . patient receive bisphosphonate within 3 week sign informed consent ; patient receive concurrent investigational therapy , receive investigational therapy within 30 day first schedule day dose ; untreated esophagitis gastric ulcer ; recent prescheduled radiotherapy bone ; patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>